Literature DB >> 27220059

Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease.

Gjin Ndrepepa1, Roisin Colleran2, Anke Luttert2, Siegmund Braun3, Salvatore Cassese2, Sebastian Kufner2, Julia Hieber2, Massimiliano Fusaro2, Karl-Ludwig Laugwitz4, Heribert Schunkert5, Adnan Kastrati5.   

Abstract

OBJECTIVES: The aim of the study was to investigate the association between gamma-glutamyl transferase (GGT) activity and mortality in patients with diabetes mellitus and coronary artery disease (CAD). DESIGN AND METHODS: The study included 1448 patients with diabetes and angiography-proven CAD who underwent percutaneous coronary intervention (PCI). Baseline GGT measurements were available in all patients. The primary outcome was 3-year mortality.
RESULTS: Patients were divided into 3 groups: a group consisting of patients with a GGT activity in the 1st tertile (GGT≤29.4U/L; n=487), a group consisting of patients with a GGT activity in the 2nd tertile (GGT>29.4-52.5U/L; n=479) and a group consisting of patients with GGT in the 3rd tertile (GGT>52.5U/L; n=482). Overall, there were 179 deaths: 46 (11.9%), 49 (12.1%) and 84 deaths (21.4%) among patients of the 1st, 2nd and 3rd GGT tertiles, respectively (adjusted hazard ratio [HR]=1.25, 95% confidence interval [CI] 1.05-1.49, P=0.011). Cardiac death occurred in 101 patients: 22 (5.8%), 30 (7.2%) and 49 deaths (12.9%) among patients of the 1st, 2nd and 3rd GGT tertiles, respectively (adjusted HR=1.23 [0.96-1.58], P=0.104, with risk estimates calculated per standard deviation increase in the logarithmic scale of GGT). GGT improved the risk prediction of models of all-cause (P=0.020) but not cardiac (P=0.135) mortality (P values show the difference in C-statistics between the models without and with GGT).
CONCLUSION: In patients with diabetes and CAD treated with PCI, elevated GGT was independently associated with the risk of 3-year all-cause mortality.
Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Diabetes; Gamma-glutamyl transferase; Mortality

Mesh:

Substances:

Year:  2016        PMID: 27220059     DOI: 10.1016/j.clinbiochem.2016.05.018

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

Review 1.  Gamma-glutamyl transferase and cardiovascular disease.

Authors:  Gjin Ndrepepa; Adnan Kastrati
Journal:  Ann Transl Med       Date:  2016-12

2.  Early Prediction for Prediabetes and Type 2 Diabetes Using the Genetic Risk Score and Oxidative Stress Score.

Authors:  Ximei Huang; Youngmin Han; Kyunghye Jang; Minjoo Kim
Journal:  Antioxidants (Basel)       Date:  2022-06-17

3.  Serum gamma-glutamyltransferase is not associated with subclinical atherosclerosis in patients with type 2 diabetes.

Authors:  Hye Eun Yoon; Eun Young Mo; Seok Joon Shin; Sung Dae Moon; Je Ho Han; Eun Sook Kim
Journal:  Cardiovasc Diabetol       Date:  2016-08-05       Impact factor: 9.951

4.  Associations between fatty liver index and asymptomatic intracranial vertebrobasilar stenosis in Chinese population.

Authors:  Jing Qiu; Zhiwei Zhou; Jie Wang; Yiying Wang; Chunxing Liu; Xingxiang Liu; Yunfang Xu; Lugang Yu; Hui Zhou; Jie Lin; Zhirong Guo; Chen Dong
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

5.  KDM3A inhibition attenuates high concentration insulin‑induced vascular smooth muscle cell injury by suppressing MAPK/NF‑κB pathways.

Authors:  Bo-Fang Zhang; Hong Jiang; Jing Chen; Xin Guo; Qi Hu; Shuo Yang
Journal:  Int J Mol Med       Date:  2017-12-29       Impact factor: 4.101

6.  Prognostic value of long-term gamma-glutamyl transferase variability in individuals with diabetes: a nationwide population-based study.

Authors:  Da Young Lee; Kyungdo Han; Ji Hee Yu; Sanghyun Park; Ji A Seo; Nam Hoon Kim; Hye Jin Yoo; Sin Gon Kim; Seon Mee Kim; Kyung Mook Choi; Sei Hyun Baik; Yong Gyu Park; Nan Hee Kim
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.